SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Corcept Therapeutics Incorporated (CORT)
CORT 72.91-0.8%12:58 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mopgcw who wrote (5)7/26/2004 6:43:48 PM
From: tuck   of 32
 
What's interesting about CORLUX is that it is also used for terminating pregnancy at similar doses. In that indication, it is known as RU-486. Remember the big controversy about it? FDA finally approved, long after its European counterpart did. Anyhow, this implies a pretty easy regulatory path for CORLUX if it can meet efficacy hurdles. I see the company is being pretty thorough about establishing that, by soon conducting pivotal trials to be completed in '06. This would imply a launch in '07.

Here's one of the earlier studies:

>>Biol Psychiatry. 2002 Sep 1;52(5):386-92.

An open label trial of C-1073 (mifepristone) for psychotic major depression.

Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF.

Corcept Therapeutics Inc., Menlo Park, California 94025, USA.

BACKGROUND: The rationale for treating patients with psychotic major depression (PMD) with glucocorticosteroid receptor (GR) antagonists is explained. METHODS: Thirty patients with PMD, with Hamilton Rating Scale for Depression (HAMD-21) scores of 18 or greater, were assigned in an open label trial to receive 50 mg, 600 mg, or 1200 mg of mifepristone for 7 days. RESULTS: All the subjects completed the protocol; there were no dropouts. Side effects were mild and sporadic. Of 19 subjects in the combined 600- and 1200-mg group, 13 had a 30% or greater decline in their Brief Psychiatric Rating Scale (BPRS) scores, compared with 4 of 11 in the 50-mg group. In the 600- and 1200-mg group, 12 of 19 subjects showed a 50% decline in the BPRS positive symptom subscale, a more sensitive index for the symptoms seen in PMD, compared with 3 of 11 in the 50-mg group; 8 of 19 subjects in the 600- and 1200-mg group had a 50% decline in the HAMD-21, compared with 2 of 11 in the 50-mg group. CONCLUSIONS: These results suggest that short term use of GR antagonists may be effective in the treatment of psychotic major depression and that further blinded studies are warranted.<<

The Society of Biological Psychiatry is pretty close-fisted about abstracts from this meeting. Can't even find reference to the 2004 meeting on the web site.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext